{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:55:13Z","timestamp":1794369313930,"version":"4.9.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ygyno.2020.07.031","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T11:36:22Z","timestamp":1596281782000},"page":"88-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment"],"prefix":"10.1016","volume":"159","author":[{"given":"Jung-Min","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Hays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Choyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minshu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail Baris","family":"Turkbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori M.","family":"Minasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise C.","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.07.031_bb0005","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2020.07.031_bb0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ygyno.2014.08.033","article-title":"The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer","volume":"135","author":"Secord","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0015","series-title":"Angiogenesis Inhibitors in Cancer Therapy: Mechanistic Perspective on Classification and Treatment Rationales","first-page":"712","volume":"170","author":"El-Kenawi","year":"2013"},{"key":"10.1016\/j.ygyno.2020.07.031_bb0020","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.13310","article-title":"Bevacizumab in ovarian cancer: a critical review of phase III studies","volume":"8","author":"Rossi","year":"2017","journal-title":"Oncotarget"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2020.07.031_bb0025","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","article-title":"Anti-angiogenic agents in ovarian cancer: past, present, and future","volume":"27","author":"Monk","year":"2016","journal-title":"Ann. Oncol."},{"issue":"Suppl. 24","key":"10.1016\/j.ygyno.2020.07.031_bb0030","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1002\/cncr.32500","article-title":"Treatment of recurrent epithelial ovarian cancer","volume":"125","author":"Pignata","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.07.031_bb0035","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2147\/OTT.S155425","article-title":"First-line treatment of women with advanced ovarian cancer: focus on bevacizumab","volume":"12","author":"Marchetti","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0040","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10555-014-9538-9","article-title":"Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches","volume":"34","author":"Choi","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","article-title":"Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?","volume":"13","author":"Gotink","year":"2010","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ygyno.2020.07.031_bb0055","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3892\/ijo.2014.2334","article-title":"The emerging role of anti-angiogenic therapy in ovarian cancer (review)","volume":"44","author":"Conteduca","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0060","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0065","series-title":"For Ovarian Cancer","first-page":"1049","volume":"22","author":"Leone Roberti Maggiore","year":"2013"},{"key":"10.1016\/j.ygyno.2020.07.031_bb0070","series-title":"Sorafenib for the Treatment of Advanced Renal Cell Carcinoma","first-page":"7271","volume":"12","author":"Kane","year":"2006"},{"key":"10.1016\/j.ygyno.2020.07.031_bb0075","first-page":"379","article-title":"FDA approves Sorafenib for patients with inoperable liver Cancer","volume":"134","author":"Lang","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ygyno.2020.07.031_bb0080","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2147\/OTT.S49430","article-title":"Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer","volume":"7","author":"McFarland","year":"2014","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0085","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2007.10.8332","article-title":"Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity","volume":"26","author":"Azad","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0090","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.bjc.6605514","article-title":"Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity","volume":"102","author":"Lee","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.07.031_bb0095","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1158\/1078-0432.CCR-08-1141","article-title":"Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy","volume":"15","author":"Azad","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fonc.2015.00123","volume":"5","author":"Lee","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0105","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/cncr.27916","article-title":"Feasibility and safety of sequential research-related tumor core biopsies in clinical trials","volume":"119","author":"Lee","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.07.031_bb0110","series-title":"In. @MDAndersonNews","author":"Functional Proteomics RPPA Core Facility","year":"2020"},{"key":"10.1016\/j.ygyno.2020.07.031_bb0115","first-page":"186","article-title":"The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment","volume":"16","author":"Turkbey","year":"2010","journal-title":"Diagn. Interv. Radiol."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0120","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"10.1016\/j.ygyno.2020.07.031_bb0125","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1172\/JCI74035","article-title":"Predicting time to ovarian carcinoma recurrence using protein markers","volume":"123","author":"Yang","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","article-title":"Angiogenesis in cancer","volume":"2","author":"Nishida","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0135","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0140","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0145","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0150","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0155","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0160","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0165","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.5506","article-title":"Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17","author":"Pignata","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0170","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ygyno.2019.03.246","article-title":"Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer","volume":"153","author":"Secord","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0175","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","article-title":"Bevacizumab-induced hypertension: clinical presentation and molecular understanding","volume":"182","author":"Li","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0180","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0185","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-13-3203","article-title":"Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins","volume":"20","author":"Sanmamed","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0190","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.7150\/thno.22536","article-title":"GRO-alpha and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1\/NFkappaB signaling cascade","volume":"8","author":"Yung","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.ygyno.2020.07.031_bb0195","first-page":"2365","article-title":"Prognostic value of serum IL-8 and IL-10 in patients with ovarian cancer undergoing chemotherapy","volume":"17","author":"Zhang","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ygyno.2020.07.031_bb0200","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00109-013-1080-7","article-title":"The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review","volume":"91","author":"Maccio","year":"2013","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.ygyno.2020.07.031_bb0205","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1186\/1471-2407-14-696","article-title":"Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer","volume":"14","author":"Sallinen","year":"2014","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2020.07.031_bb0210","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"O\u2019Malley","year":"2020","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820336775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820336775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:50:19Z","timestamp":1758772219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820336775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0090825820336775"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.031","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}